Siemens at the Clinical Diagnostics & Research Online Conference 2015

Siemens at the Clinical Diagnostics & Research Online Conference 2015
Contact Us

We proudly sponsored speaker sessions covering the following topics at the Clinical Diagnostics and Research online conference:

  • Keynote session: Evolution of Standardization in Laboratory Medicine
  • Improving Diagnostic Testing and Interpretation of Chronic Kidney Disease (CKD)
  • Graves’ Disease Assessment: Current Trends in Laboratory Testing

Watch the speaker sessions.

Keynote: Evolution of Standardization in Laboratory Medicine

November 11th - 7:30 am PT


Linda Thienpont, PhD, PHARM, Clinical Chemist
Professor of Analytical Chemistry, Statistics and Quality Control, Method Development and Validation;
Director of the Laboratory for Analytical Chemistry ID-MS Reference Laboratory, University of Ghent, Belgium


Prof. Dr. Linda Thienpont has spent most of her career developing and validating reference measurement procedures using isotope dilution-gas chromatography and liquid chromatography-mass spectrometry for the analysis of many components in serum/plasma. These have included clinical chemistry analytes, steroid hormones, thyroid hormones, peptides, and vitamin metabolites. In addition to chairing the IFCC Committee on the Standardization of Thyroid Hormones, she has worked with the eminent standardization and certification authorities to establish metrological traceability and assess the trueness/accuracy of hierarchically lower (routine) methods in laboratory medicine. She has worked in research projects with different IVD manufacturers worldwide and been involved in proficiency testing/external quality assessment organizations, accreditation bodies, and governmental offices. She has been involved in many educational campaigns and has published more than 168 scientific papers.

There is agreement among clinicians that laboratory analyses are indispensable for correct diagnosis of disease, therapy, and patient monitoring. It is evident that laboratory data should be comparable and independent of measurement system, time, and location, but this often is not the case. The concept of standardization or establishment of metrological traceability has been developed to solve these challenges. Understanding the benefits of traceability of lab results in public healthcare is of increasing importance and enables the interpretation of results against common reference intervals, development of evidence-based clinical guidelines, translation of research data into patient care and prevention activities, and the inclusion of lab data in electronic patient records. This presentation explains the standardization concept in detail, considering both defined analytes (e.g., creatinine, cholesterol, glucose) and analytes that are not unequivocally defined. One example will focus on measurement of serum TSH, a typical heterogeneous glycoprotein. Potential noncommutability encountered with artificial reference materials in the standardization/harmonization process will be discussed, as will the use of large panels of clinically relevant samples to ensure commutability. Implementation in practice may be the biggest challenge, particularly in cases where the standardization process has a major impact on the values with which the clinical lab community is familiar. Hence, education of all stakeholders is critical. In addition, the need for continual assessment will be demonstrated by examples.
Learning Objectives:

  • Identify the rationale for and benefit of standardization in lab medicine.
  • Describe the basic design and evolution of the standardization process.
  • Learn the importance of using panels of clinically relevant samples in the standardization process.
  • Identify requirements to be met before standardization can be implemented.
  • Understand what is required after standardization.

Improving Diagnostic Testing and Interpretation of Chronic Kidney Disease (CKD)

November 11th - 1:30 pm PT


Kevin J. Martin, MD, MB, BCh, FASN
Professor of Internal Medicine
Director of the Division of Nephrology
Saint Louis University School of Medicine
Saint Louis, MO, USA


Dr. Martin is Director of the Division of Nephrology at Saint Louis University and Professor of Internal Medicine. He has served as Chairman of the General Medicine B Study Section of the National Institutes of Health. Dr. Martin’s clinical research interests include parathyroid hormone, Vitamin D metabolism and secondary hyperthyroidism. He has authored 230 publications in professional journals, including The New England Journal of Medicine, Kidney International, and The American Journal of Kidney Diseases and Clinical Journal of the American Society of Nephrology.

Stuart M. Sprague, DO, FACP, FASN, FNKF
Chief, Division of Nephrology and Hypertension;
Director of Nephrology Research
NorthShore University HealthSystem
Chicago, IL, USA


Dr. Sprague is chief, Division of Nephrology and Hypertension, and director of nephrology research at NorthShore University HealthSystem and clinical professor of medicine at the University of Chicago Pritzker School of Medicine, Chicago, IL, USA. His clinical focus includes chronic kidney disease, dialysis, end-stage renal failure, and osteoporosis in chronic kidney disease.

Diagnosis and management of CKD requires a spectrum of diagnostic tests to not only diagnose kidney function but also determine the status of other complications due to CKD, including creatinine, BUN, phosphorous, calcium, intact PTH, vitamin D, cystatin C, urinary albumin, urinalysis, EPO, and cardiac markers. In order to best assist physicians in the management of CKD, it is important that the laboratory is well versed in the specific tests used, improvements made to tests over time, and opportunities for improvement. Clinicians should know how to use tests appropriately in patient treatment across the continuum of CKD care.

Learning Objectives:

  • Understand improvements in CKD diagnostic testing and also examine other opportunities for analytical improvement focusing on the measurement of PTH, vitamin D compounds, and bone markers.
  • Review case studies demonstrating the clinical application of these tests for patient management across the spectrum of CKD and ESRD.

Graves' Disease Assessment: Current Trends in Laboratory Testing

November 12th - 10:30 am PT


Damien Gruson, PhD
Pharmacist, Specialist in Laboratory Medicine
Professor, Associated Laboratory Director, Endocrine Biology, St-Luc University Hospital, Researcher, Endocrinology Diabetes and Nutrition, Catholic University of Louvain, Belgium


Professor Damien Gruson was awarded his degree of Pharmacist and later of Specialist in Laboratory Medicine from the Catholic University of Louvain, Brussels,Belgium. He joined the Department of Laboratory Medicine of the St-Luc University Hospital in 2008. He is now associated laboratory director and leading Endocrine Biology. He is also member of the research unit on Endocrinolgy Diabetes and Nutrition of the Catholic University of Louvain. Pr. D. Gruson has published numerous articles in several international peer-reviewed journals. Pr. D. Gruson is also a member of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Communication and Publication Division, IFCC task force for young scientists (Chair between 2010 and 2012 and now consultant), a member of the Lipoproteins and cardiovascular diseases of the American Association of Clinical Chemistry and member of the committee on distance learning of the IFCC.


Hyperthyroidism is an autoimmune disorder caused by the thyroid stimulating antibody (TSI), active against the thyroid-stimulating hormone (TSH) receptor, which stimulates the gland to synthesize and secrete excess thyroid hormone. It affects approximately 1.5% of the worldwide population. Graves’ disease is the most common cause of hyperthyroidism.

Fast and proper differential diagnosis of Graves’ disease is vital to initiating appropriate treatment as soon as possible. Patient history, physical examination, and diagnostic tools such as imaging and laboratory testing are necessary for proper diagnosis. Choosing the right laboratory tests and interpreting them correctly are critical components of Graves’ disease diagnosis. Currently, a variety of thyroid antibody and hormone assays are available. Understanding the differences between these tests is important to choosing the right assay.

Learning Objectives:

  • Understand how clinicians diagnose and monitor Graves’ disease, and why the TSI assay is beneficial from the clinician’s point of view.
  • Learn about the differences between the TSI assay and a thyroid receptor antibody test called TRab.
  • Review the laboratory needs for proper Graves’ disease assessment.